Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV Renal function test 200 mg/kg via infusion over 3-5 minutes. May repeat test dose, if inadequate response. Oliguric phase of renal failureAs 10, 15 or 20% solution: 50-200 g in a 24 hour period. Adjust rate of infusion to maintain urine outflow of at least 30-50 mL/hour. Raised intracranial pressure; Raised intraocular pressure; Cerebral oedema As 10, 15 or 20% solution: 1.5-2 g/kg via infusion over 30-60 minutes. Irrigation Transurethral prostatic resection Use 2.5-5% soln for bladder irrigation.
Pulmonary congestion or oedema; intracranial bleeding; CHF; metabolic oedema with abnormal capillary fragility; anuria due to severe renal disease; severe dehydration.
Special Precautions
Hypervolaemia; urinary tract obstruction; check for signs of fluid and electrolyte imbalance. Should not be administered with whole blood. Pregnancy, lactation.
Adverse Reactions
Fluid and electrolyte imbalance; acidosis (with high doses). Nausea, vomiting, thirst; headache, dizziness, convulsions, chills, fever; tachycardia, chest pain; blurred vision; urticaria and hypotension or hypertension; acute renal failure; skin necrosis; thrombophloebitis.
Drug Interactions
Increased nephrotoxicity with ciclosporin.
ATC Classification
V04CX04 - mannitol
R05CB16 - mannitol ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
B05CX04 - mannitol ; Belongs to the class of other solutions used as irrigating solutions.
B05BC01 - mannitol ; Belongs to the class of solutions producing osmotic diuresis used in I.V. solutions.
A06AD16 - mannitol ; Belongs to the class of osmotically acting laxatives.
Disclaimer: This information is independently developed by CIMS based on mannitol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in